India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
The emergence of new infections in India is a growing concern
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Subscribe To Our Newsletter & Stay Updated